GMP Requirements
This page provides a plain English reference for gmp requirements under China's NMPA regulatory framework. Full content to be completed during editorial review.
Regulatory basis
- MDSAR 2021 (State Council Order No. 739)
- Medical Device Production Supervision and Administration Measures (NMPA Order No. 53)
- YY/T 0287-2017 (equivalent to ISO 13485:2016)
Key requirements
See NMPA GMP guidance for published on www.nmpa.gov.cn and YY/T 0287-2017 detailed GMP compliance is verified through both scheduled routine inspections and unannounced compliance inspections. inspection requirements and GMP standards applicable to your device class and manufacturing scope.
- NMPA — www.nmpa.gov.cn
- CMDE — www.cmde.org.cn
- NMPA Medical Device Registration Query — datasearch.nmpa.gov.cn
Content on this site is written with AI assistance and is intended as a navigation aid only. Always verify against official NMPA sources before making regulatory decisions. Not affiliated with NMPA or any Chinese Government body. Not legal or regulatory advice.
NMPA GMP Framework: NMPA GMP requirements are mandated by MDSAR 2021 and detailed in the Medical Device Production Supervision and Administration Measures (NMPA Order No. 53). YY/T 0287-2017 serves as the quality management system standard. Key GMP requirements include: (1) Management Responsibility—defined quality policy, organizational structure, and management review; (2) Design and Development—controlled design processes with validation; (3) Document Control—procedures for creation, review, approval, and change management; (4) Production and Service Control—controlled manufacturing with defined work instructions and in-process controls; (5) Purchasing Control—supplier evaluation and material acceptance; (6) Identification and Traceability—batch tracking and recall capability; (7) Production and Service Provision—cleanliness, contamination prevention, and process controls; (8) Inspection, Measurement, Analysis and Improvement—testing protocols, statistical analysis, and CAPA; (9) Post-Market Surveillance—adverse event monitoring and complaint handling. Compliance is verified through scheduled and unannounced GMP inspections.